Intravitreal bevacizumab monotherapy for choroidal neovascularisation secondary to choroidal osteoma

Papastefanou, Vasilios P.; Pefkianaki, Maria; Harby, Lamis Al; Arora, Amit; Cohen, Victoria M L; Andrews, Richard M.; Sagoo, Mandeep S.

doi:10.1038/eye.2016.50

Cited by 24 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are no clinical guidelines for anti-VEGF therapy of CNV secondary to CO. [ 9 ] In the present case, the patient was treated with intravitreal aflibercept injection. We compared the morphologic changes in the out retina layer before and after treatment, 1 month follow-up, the SRF was increased on OCT B-scan, but the flow areas on OCTA were significantly narrower than the initial situation, and the BCVA was improved to 20/30, however, 2 months after injection, the CNV reoccurred, the SRF was decreased, however, the flow areas of CNV were expanded, and the BCVA was decreased.…”

Section: Discussionmentioning

confidence: 93%

Optical coherence tomography angiography findings of choroidal neovascularization secondary to decalcified choroidal osteoma treated with intravitreal aflibercept

Yao¹,

Wang

Zhao³

et al. 2020

Medicine

View full text Add to dashboard Cite

Introduction: Choroidal osteoma (CO) is a rare benign ocular tumor characterized by ossifying choroid lesions. To the best of our knowledge, this is the first detailed report to describe the optical coherence tomography angiography (OCTA) findings of choroidal neovascularization (CNV) complicated by a rare decalcified CO following intravitreal aflibercept injection. Patient concerns: A 26-year-old woman presented with a spontaneous but painless reduction in visual acuity in her left eye that had commenced 5 days prior. Diagnosis: Clinical manifestations and multimodal imaging, including OCTA, spectral-domain optical coherence tomography, fundus fluorescein angiography and indocyanine green angiography, indicated decalcified CO with CNV. Interventions: After receiving an appropriately detailed explanation of the procedure, the patient was treated via intravitreal aflibercept(2.0 mg) injection once. Outcomes: One month after the therapy, OCTA revealed that the flow areas of CNV were narrowed, the best-corrected visual acuity was improved to 20/30, however, 2 months follow-up OCTA revealed that the CNV reoccurred, the best-corrected visual acuity was dropped to 20/50. Conclusion: Intravitreal aflibercept injection was an effective treatment for CO with CNV, but the effects may not last long. The OCTA findings provide a better appreciation of evaluating the effects of intravitreal aflibercept injection for CO complicating CNV.

show abstract

Section: Discussionmentioning

confidence: 93%

Optical coherence tomography angiography findings of choroidal neovascularization secondary to decalcified choroidal osteoma treated with intravitreal aflibercept

Yao¹,

Wang

Zhao³

et al. 2020

Medicine

View full text Add to dashboard Cite

show abstract

“…FA has been the gold standard for the diagnosis of CNV. Both classic and occult subtypes have been reported, with the predominance of classic components [40]. However, inherent patchy hyperfluorescence of the tumor and RPE abnormalities may either masquerade or obscure leakage from CNV.…”

Section: Choroidal Osteomamentioning

confidence: 99%

Choroidal Neovascularization Associated with Rare Entities

Anvari

Naseripour

Falavarjani

2020

Choroidal Neovascularization

View full text Add to dashboard Cite

Choroidal nevi are usually found incidentally during routine ophthalmoscopic examination. The prevalence ranges from 4 to 8% in general white population [1,2] making it the most common benign melanocytic intraocular tumor in adults [3]. Clinically, choroidal nevi appear as flat or slightly elevated, round or oval pigmented gray-brown (and sometimes amelanotic) lesions with well-defined margins. They are located deep to the retina, evenly distributed in all four quadrants of fundus and more common in postequatorial region [4].Although mostly asymptomatic, choroidal nevi should be observed for possible malignant transformation [5]. They may result in decreased visual acuity by inducing secondary changes in overlying retinal pigment epithelium (RPE) and retina including RPE atrophy or secondary fibrous metaplasia, pigment epi-

show abstract

“…Osteomas in particular are most likely to cause structural changes in the photoreceptor-pigmentepithelium complex predisposing to subsequent CNV development. Although masses as such rarely cause a reduction in visual acuity, CNV is often associated with a massive loss in visual acuity [33].…”

Section: Subretinal Tumorsmentioning

confidence: 99%

Statement of the BVA, the DOG, and the RG on treatment of choroidal neovascularization in diseases other than neovascular age-related macular degeneration

2018

Ophthalmologe

View full text Add to dashboard Cite

Leitlinien, Stellungnahmen und Empfehlungen (e. g., patients requiring frequent re-injections), a different treatment regimen (e. g., treat and extend) can be considered in the further course. 9. If visual acuity drops below 0.05 on anti-VEGF treatment, or no further positive treatment outcome is expected (e. g., in the presence of atrophy and/or fibrosis), treatment should be discontinued, unless there is a clear possibility that visual acuity could increase again to over 0.05 under treatment. 10. If no improvement is seen under therapy with a certain VEGF inhibitor, or if deterioration occurs, one can consider switching to an alternative VEGF inhibitor.

show abstract

Intravitreal bevacizumab monotherapy for choroidal neovascularisation secondary to choroidal osteoma

Cited by 24 publications

References 39 publications

Optical coherence tomography angiography findings of choroidal neovascularization secondary to decalcified choroidal osteoma treated with intravitreal aflibercept

Optical coherence tomography angiography findings of choroidal neovascularization secondary to decalcified choroidal osteoma treated with intravitreal aflibercept

Choroidal Neovascularization Associated with Rare Entities

Statement of the BVA, the DOG, and the RG on treatment of choroidal neovascularization in diseases other than neovascular age-related macular degeneration

Contact Info

Product

Resources

About